

### **Amendments to the Specification**

**A.** Paragraph [0119] of the application, published as US Patent Application Publication No. 2008/0250514, is amended as follows:

[0119] Sequence information on mouse  $\beta$ -actin was obtained from the mouse genome information disclosed by NCBI (~~<http://www.ncbi.nlm.nih.gov/>~~ [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/)) and the Jackson laboratory (~~<http://www.jax.org/>~~ [www.jax.org](http://www.jax.org/)). The primers comprising the following sequences were synthesized (Espec oligo service Co.): mAct5-F1 (5'-GGGAGTGA~~CT~~CTCTGTCCATTCAATCC-3'/SEQ ID NO: 9) and mAct5-R1 (5'-TTGTGACGACCAGCGCAGCGATATCG-3'/SEQ ID NO: 10). The promoter region (1,577 bp) of mouse  $\beta$ -actin was amplified by PCR. PCR was carried out using TaKaRa LA Taq with GC Buffer (cat. RR02AG) from Takara Bio as reagent and Mouse Genomic DNA (cat. 6650-1) from Clontech as template DNA.

**B.** Paragraph [0199] of the application, published as US Patent Application Publication No. 2008/0250514, is amended as follows:

[0199] The primers mRas-F1 (5'-TCCTGGATTGGCAGCCGCTGTAGAAGC-3'/SEQ ID NO: 34) and mRas-R1 (5'-GTTTCATCTGGCTAGCTGAGGTCAGTGC-3'/SEQ ID NO: 35) were synthesized (Espec oligo service Co.) based on the information of GenBank Accession No. M30733 disclosed at NCBI (~~<http://www.ncbi.nlm.nih.gov/>~~ [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/)). Using the primers, the mouse c-H-ras gene was amplified by PCR. PCR was carried out using TaKaRa LA Taq with GC Buffer from Takara Bio as the reagent, and Embryo Marathon-Ready DNA day 15 (cat. 7459-1) from Clontech as the template cDNA.